Receptor
Receptor is a New York-based venture capital firm founded in 2021 that invests exclusively in early-stage psychedelic medicine companies developing novel therapeutics for mental health conditions, backing a portfolio that includes Beckley Psytech, Delix, Cybin, and Psilera.
- Company typePrivate
- Founded2021
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Receptor does
Receptor (legal name Receptor Partners, LLC) is a New York-based venture capital firm founded in 2021 that invests exclusively in the psychedelic medicine sector. The firm deploys equity capital and provides strategic support to early-stage companies developing novel therapeutic approaches for mental health conditions. Its stated positioning is investing in "the future of psychedelic medicine," addressing a funding gap in psychedelic medicine research and development and supporting innovation in mental health treatment through strategic capital deployment.
Receptor is a private investment entity rather than a product or software company; it does not sell products or services and has no disclosed pricing, revenue model, or commercial distribution. Its disclosed portfolio comprises eight companies developing psychedelic-based therapeutics and related technologies: Beckley Psytech, Psilera, Mind State Design, Brightminds (Brightminds Bio), Tactogen, Delix (Delix Therapeutics, focused on non-hallucinogenic psychedelic analogs), Freedom Bio, and Cybin. The firm characterizes these as portfolio company investments in its "core" strategic tier.
The company is a small operation (1–10 employees) headquartered in New York, United States, structured as an LLC with no disclosed parent, subsidiaries, institutional backers, or public listing. Investor relations are handled through a single disclosed contact ([email protected]). As a venture firm, it likely relies on private networking, industry conferences, and direct outreach for deal sourcing and investor relations, though marketing activities are not publicly disclosed.
Receptor firmographics
Firmographics- Name
- Receptor
- Legal name
- Receptor Partners, LLC
- Website
- https://receptor.vc
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Receptor is a New York-based venture capital firm founded in 2021 that invests exclusively in early-stage psychedelic medicine companies developing novel therapeutics for mental health conditions, backing a portfolio that includes Beckley Psytech, Delix, Cybin, and Psilera.
- Ownership category
- akta.pro rank
Receptor industry classification
Industry- Product category
- Venture Capital (Psychedelic Medicine)
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Receptor is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Receptor business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Receptor product offering
Product offeringCore offering
Receptor is a venture capital firm that provides equity investment capital to early-stage companies developing psychedelic-based therapeutics and supporting technologies for mental health conditions. The firm deploys and manages a thematic portfolio across psychedelic drug developers and research platforms rather than selling any standalone product or service. Investment activity is concentrated on portfolio companies such as Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin.
Product overview
Receptor is a venture capital firm that provides investment capital and strategic support to early-stage companies in the psychedelic medicine sector. The firm does not offer a product platform or software services; instead, it deploys equity investment across a portfolio of companies developing psychedelic-based therapeutics and related technologies. Receptor's portfolio includes Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin, representing the firm's investment focus rather than a product ecosystem.
Differentiator
Problem solved
Functional benefit
Companies that use Receptor
Customer profileIdeal customer profiles1 record
Receptor technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Receptor partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
Receptor competitors and assessment
Company assessmentMarket position
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Receptor social profiles
Digital presenceReceptor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Receptor leadership team
Management profileNumber of profiles
Receptor funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Receptor M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Receptor
What does Receptor do?
Receptor is a venture capital firm that provides equity investment capital to early-stage companies developing psychedelic-based therapeutics and supporting technologies for mental health conditions. The firm deploys and manages a thematic portfolio across psychedelic drug developers and research platforms rather than selling any standalone product or service. Investment activity is concentrated on portfolio companies such as Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin.
Is Receptor a public or private company?
Receptor is a private company. It is classified as unknown and is currently operating.
When was Receptor founded?
Receptor was founded in 2021. It employs 1 to 10 people.
Where is Receptor based?
Receptor is headquartered in New York, United States, in the North America region.
Does Receptor have an API?
No public API is recorded for Receptor.
What industry is Receptor in?
Receptor's product category is Venture Capital (Psychedelic Medicine). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 523940 and its SIC code is 6282.